204 results about "Cyclotide" patented technology

In one aspect, the present disclosure encompasses polymerization systems for the copolymerization of CO2 and epoxides comprising 1) a catalyst including a metal coordination compound having a permanent ligand set and at least one ligand that is a polymerization initiator, and 2) a chain transfer agent having two or more sites that can initiate polymerization. In a second aspect, the present disclosure encompasses methods for the synthesis of polycarbonate polyols using the inventive polymerization systems. In a third aspect, the present disclosure encompasses polycarbonate polyol compositions characterized in that the polymer chains have a high percentage of —OH end groups and a high percentage of carbonate linkages. The compositions are further characterized in that they contain polymer chains having an embedded polyfunctional moiety linked to a plurality of individual polycarbonate chains.

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

The methods of the present invention comprise the steps of: providing a feedstock stream comprising an epoxide and carbon monoxide; contacting the feedstock stream with a metal carbonyl in a first reaction zone to effect conversion of at least a portion of the provided epoxide to a beta lactone; directing the effluent from the first reaction zone to a second reaction zone where the beta lactone is subjected to conditions that convert it to a compound selected from the group consisting of: an alpha beta unsaturated acid, an alpha beta unsaturated ester, an alpha beta unsaturated amide, and an optionally substituted polypropiolactone polymer; and isolating a final product comprising the alpha-beta unsaturated carboxylic acid, the alpha-beta unsaturated ester, the alpha-beta unsaturated amide or the polypropiolactone.

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus, such as a detectable label. Along with therapeutic utilities, these peptide based compounds can be used in assays useful for screening, monitoring, diagnostic and / or dosing purposes.

This invention relates to a method of preparing poly(alkylene carbonate) that has a molecular weight and polymer chain structure precisely controlled by adding a chain transfer agent composed of a compound having an alcohol or carboxylic acid functional group upon alternating copolymerization of an epoxide compound and carbon dioxide using a catalyst composed of a trivalent metal complex compound synthesized from a quaternary ammonium salt-containing Salen type ligand, and to a polymer compound prepared thereby. According to this invention, the polymer compound having a star-shaped chain as well as the polymer having a linear chain can be prepared. The low-molecular-weight poly(alkylene carbonate) has an —OH terminal group and can be used alone as a coating agent, etc., and also in mixtures with an isocyanate compound and thus can be easily utilized to prepare polyurethane.

Poly(ester-acrylate) and poly(ester / epoxide) dendrimers. These materials can be synthesized by utilizing the so-called “sterically induced stoichiometric” principles. The preparation of the dendrimers is carried out by reacting precursor amino / polyamino-functional core materials with various branch cell reagents. The branch cell reagents are dimensionally large, relative to the amino / polyamino-initiator core and when reacted, produce generation=1 dendrimers directly in one step. There is also a method by which the dendrimers can be stabilized and that method is the reaction of the dendrimers with surface reactive molecules to pacify the reactive groups on the dendrimers.

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

The present disclosure provides novel methods of making aluminum complexes with utility for promoting epoxide carbonylation reactions. Methods include reacting neutral metal carbonyl compounds with alkylaluminum complexes.

The invention provides a preparation method of aliphatic polycarbonate polyol. The preparation method comprises the following steps: carrying out copolymerization on carbon dioxide and an epoxy compound in the presence of a metalloporphyrin complex and a chain transfer agent to obtain aliphatic polycarbonate polyol, wherein the metalloporphyrin complex is as shown in a formula (I) or a formula (II), the quaternary ammonium salt, the quaternary phosphorus salt or the organic base group with great steric hindrance of the metalloporphyrin complex ensure that an electronic environment of ligand is more conducive to the stabilization of a metal active center, and after the metalloporphyrin complex and the chain transfer agent jointly act on the copolymerization, the content of the obtained by-product cyclic carbonate is low. Experimental results show that the content of the cyclic carbonate in the aliphatic polycarbonate polyol prepared by the preparation method is lower than 3%; and in addition, the content of carbonate in polycarbonate polyol prepared by the preparation method is as high as 85%-98%.

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

The invention discloses a fluorine-containing titanium-silicon molecular sieve with a MWW (Manual Wire Wrap) structure and a preparation method and an application thereof. In the molecular sieve, a fluorine atom is connected with a framework silicon atom in the form of a chemical bond, an XRD (X-Ray Diffraction) spectrogram contains a characteristic spectral line of the molecular sieve with the MWW structure, and characteristic peaks of -150+ / -5ppm and -143+ / -5ppm appear in a 19FMAS-NMR (19 File Management Assistant For Server-Nuclear Magnetic Resonance) spectrogram; the preparation method comprises the following steps of: synthesizing a boron-containing parent body, post-treating, baking and the like; and the molecular sieve serving as a catalyst is applied to catalytic oxidation reactions of compounds containing carbon-carbon double bonds and at least one other functional group as well as reactions for catalytically synthesizing oxime. The molecular sieve has a complete crystalline state structure; according to the electronic effect of framework fluorine, the molecular sieve and higher catalytic oxidation capability; a preparation process is simple, and is easy for industrial production; synthesis of corresponding epoxides or catalytic synthesis of oxime from compounds containing carbon-carbon double bonds and at least one other functional group can be catalyzed at higher activity and high selectivity; and a reaction process is environmentally-friendly.

The present invention relates to a process comprising the steps of reacting in the presence of an epoxide opening catalyst, a substituted epoxide, and preferably a silicone containing substituted epoxide with at least one carboxylic acid and at least one protecting agent to form a vicinal dialkyl ester or a vicinal disilyl ester.

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

The invention provides a gene engineering bacteria for producing dehalogenase and realizes the industrial production of dehalogenase industrialised by culturing the gene engineering bacteria via fermentation technology. The invention also provides the use of the gene engineering bacteria; and the halogenohydrin dehalogenase produced by the gene engineering bacteria can be applied to ring-opening reaction of ortho-halogenohydrin dehalogenation epoxidation and epoxide.

The invention provides a preparation method for an aminoalkyl glucoside graft copolymer. The preparation method comprises the following steps: (1) subjecting alkyl glucoside, epoxide, chloride and anacidic catalyst to a reaction so as to obtain a first intermediate; (2) reacting the first intermediate with alicyclic amine so as to obtain a second intermediate; and (3) under the action of an initiator, subjecting the second intermediate, acrylamide and 2-acrylamide-2-methylpropanesulfonic acid to a reaction so as to obtain the aminoalkyl glucoside graft copolymer. With the method provided by the invention, the aminoalkyl glucoside graft copolymer with a specific structure is prepared and has good inhibition performance, lubrication performance, filtrate loss reducing performance, and resistance to contamination by saturated salts and composite salts. Moreover, the aminoalkyl glucoside graft copolymer is free of biological toxicity. The invention also provides the aminoalkyl glucoside graft copolymer and a drilling fluid.